Physician profile
Michael B Dahl
NPI 1124013297
$7,954.30
in general payments reported to CMS, 2019-2025
41 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $265 · 2021: $833 · 2022: $1,303 · 2023: $1,003 · 2024: $1,238 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,086.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,062.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $913.96 | 2019-2025 | |
| Novo Nordisk INC | $791.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $596.63 | 2019-2024 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.78 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $348.31 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $342.65 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $258.10 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $228.68 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Amarin Pharma, INC. | $202.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.69 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $166.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $157.20 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $121.80 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.